Abstract | PURPOSE: We report on the effect that pretreating patients with phenobarbital has on averting adverse events when primidone is introduced. METHODS: RESULTS: Twenty-six patients (87%) tolerated the introduction of primidone with minimal or no adverse events. Only one patient had to discontinue primidone during the initial 4 weeks because of severe dizziness. This was the only patient in whom primidone monotherapy could not be reached because of adverse events. Three other patients experienced dizziness severe enough to interfere with their activities. This symptom disappeared in two patients after the dose was lowered; in the other patient, primidone was stopped and phenobarbital was restarted for another 4 days. No symptoms recurred when primidone was reintroduced on the fifth day. CONCLUSIONS: Pretreatment with phenobarbital can minimize the occurrence of intolerable adverse events associated with the introduction of primidone.
|
Authors | A M Kanner, J Parra, M Frey |
Journal | Epilepsia
(Epilepsia)
Vol. 41
Issue 10
Pg. 1310-4
(Oct 2000)
ISSN: 0013-9580 [Print] United States |
PMID | 11051127
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Ambulatory Care
- Child
- Child, Preschool
- Dizziness
(chemically induced)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Tolerance
- Epilepsies, Partial
(drug therapy)
- Female
- Follow-Up Studies
- Hospitalization
- Humans
- Male
- Middle Aged
- Phenobarbital
(administration & dosage, therapeutic use)
- Premedication
- Primidone
(adverse effects, therapeutic use)
- Treatment Outcome
|